| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/26/2023 | 166.67% | HC Wainwright & Co. | $13 → $16 | Maintains | Buy |
| 10/23/2023 | 133.33% | Wedbush | → $14 | Reiterates | Outperform → Outperform |
| 09/22/2023 | 133.33% | Wedbush | → $14 | Initiates Coverage On | → Outperform |
| 08/16/2023 | 350% | Baird | $15 → $27 | Maintains | Outperform |
| 08/15/2023 | 116.67% | HC Wainwright & Co. | $14 → $13 | Maintains | Buy |
| 06/08/2023 | 133.33% | HC Wainwright & Co. | → $14 | Reiterates | Buy → Buy |
| 05/10/2023 | 133.33% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 04/05/2023 | 33.33% | Citigroup | $9 → $8 | Maintains | Buy |
| 03/23/2023 | 166.67% | HC Wainwright & Co. | → $16 | Upgrades | Neutral → Buy |
| 03/21/2023 | 150% | JP Morgan | $16 → $15 | Maintains | Overweight |
| 03/21/2023 | 150% | Guggenheim | → $15 | Downgrades | Buy → Neutral |
| 03/16/2023 | 133.33% | Oppenheimer | → $14 | Upgrades | Perform → Outperform |
| 05/20/2022 | 50% | Citigroup | $10 → $9 | Maintains | Buy |
| 03/25/2022 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 03/22/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 03/22/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 11/10/2021 | 416.67% | HC Wainwright & Co. | $30 → $31 | Maintains | Buy |
| 10/08/2021 | 400% | HC Wainwright & Co. | $53 → $30 | Maintains | Buy |
| 08/11/2021 | 783.33% | HC Wainwright & Co. | $54 → $53 | Maintains | Buy |
| 07/06/2021 | 466.67% | Citigroup | → $34 | Upgrades | Neutral → Buy |
| 03/25/2021 | 800% | HC Wainwright & Co. | $52 → $54 | Maintains | Buy |
| 01/25/2021 | — | Citigroup | Downgrades | Buy → Neutral | |
| 08/13/2020 | 650% | Baird | → $45 | Initiates Coverage On | → Outperform |
| 08/03/2020 | 766.67% | HC Wainwright & Co. | → $52 | Initiates Coverage On | → Buy |
| 05/19/2020 | 650% | Guggenheim | → $45 | Initiates Coverage On | → Buy |
| 05/19/2020 | 566.67% | Jefferies | → $40 | Initiates Coverage On | → Buy |
| 05/19/2020 | 483.33% | Citigroup | → $35 | Initiates Coverage On | → Neutral |
What is the target price for ORIC Pharmaceuticals (ORIC)?
The latest price target for ORIC Pharmaceuticals (NASDAQ: ORIC) was reported by HC Wainwright & Co. on October 26, 2023. The analyst firm set a price target for $16.00 expecting ORIC to rise to within 12 months (a possible 166.67% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ORIC Pharmaceuticals (ORIC)?
The latest analyst rating for ORIC Pharmaceuticals (NASDAQ: ORIC) was provided by HC Wainwright & Co., and ORIC Pharmaceuticals maintained their buy rating.
When is the next analyst rating going to be posted or updated for ORIC Pharmaceuticals (ORIC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ORIC Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ORIC Pharmaceuticals was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
Is the Analyst Rating ORIC Pharmaceuticals (ORIC) correct?
While ratings are subjective and will change, the latest ORIC Pharmaceuticals (ORIC) rating was a maintained with a price target of $13.00 to $16.00. The current price ORIC Pharmaceuticals (ORIC) is trading at is $6.00, which is out of the analyst's predicted range.